EGF/MAPK Signaling Notes
Signaling Dynamics: Intro to EGF Pathway (BIOL 151)
Core idea: cells respond to external signals via signal transduction pathways that transmit information from the membrane to the nucleus, leading to changes in gene expression and cell behavior. Paths typically use kinases and phosphatases in cascades with feedback and protein turnover to shape duration and intensity of the response.
Key components of signal transduction:
Receptors (often receptor tyrosine kinases, RTKs, like EGFR)
Kinases and phosphatases that add/remove phosphate groups
Transcription factors that move to the nucleus and alter gene expression
G proteins and second messengers (in pathways like GPCRs) that can cross-talk with kinase cascades
Ubiquitin-dependent proteolysis for protein turnover and signal termination
Signal duration is controlled by two main factors:
Kinase/phosphatase competition and relative activities
Protein turnover via ubiquitin-proteasome system
Receptor-mediated endocytosis controls receptor availability and signal termination via
Recycling mode: receptors are returned to the membrane after signal removal
Destruction mode: receptors are directed to lysosomes for degradation
Ubiquitin-Dependent Proteolysis and Protein Turnover
Ubiquitin tags are added to specific proteins to mark them for destruction by the proteasome.
Consequence: activated proteins get destroyed and new ones are synthesized, turning signaling off unless renewed.
Conceptual sequence:
Signal present → pathway activated → downstream proteins become phosphorylated and active
Ubiquitination tags activated proteins for degradation → protein turnover resets signaling state
Example given: in a kinase cascade, if upstream kinase TK2 is inactivated by a phosphatase, downstream activation (e.g., TFa) may persist only until turnover removes phosphorylated copies and new (unphosphorylated) copies are synthesized.
Note: Phosphatases encoded by early-response genes can temporarily suppress upstream kinases, creating potential for oscillations when turnover reintroduces activity.
Negative Feedback and Oscillations in Kinase Cascades
To generate oscillations in a kinase cascade, a pathway must satisfy four conditions:
1) Activation of the pathway leads to expression/activation of a phosphatase (or other inhibitor) of pathway elements.
2) The phosphatase targets an upstream kinase and blocks its function.
3) Protein turnover deactivates kinases or transcription factors downstream of the phosphatase.
4) Inactivation of the kinases/transcription factors blocks expression and/or activation of the phosphatase.Mechanistic sequence for oscillations (example):
Signal → activation → expression of phosphatase targeting TK2
Phosphatase inactivates TK2 immediately
TK2 inactivation stops downstream activation, including TFa activity, but TFa remains active briefly due to existing phosphorylated copies
Protein turnover degrades phosphorylated TK2 and TFa; new unphosphorylated TK2 and TFa are synthesized
Once phosphatase expression ceases (or its targets are depleted), pathway can reactivate, leading to cyclical on/off states (oscillations)
Important takeaway: oscillations rely on timing between synthesis/degradation of signaling components and the feedback-controlled expression of inhibitors.
Receptor-Mediated Endocytosis: Endocytosis Modes and Outcomes
Receptor-ligand binding at the plasma membrane triggers endocytosis:
Clathrin-coated pits assemble to form coated vesicles that internalize receptors with bound ligands.
Vesicles fuse with endosomes where receptors and ligands may be sorted for fate.
Destruction mode (lysosomal degradation):
Receptors are directed to lysosomes and degraded, reducing receptor levels and terminating signaling.
Recycling mode (receptor recycling):
Receptors are recycled back to the plasma membrane after ligand removal, enabling potential re-sensitization to signal.
Visual cues from notes: “Destruction Mode” vs “Recycling Mode” are contrasted as two possible fates after endocytosis.
Implications: receptor fate influences signal duration and receptor sensitivity on a cell-by-cell basis; dysregulation can contribute to disease, including cancer when receptor recycling is enhanced or degradation is impaired.
Stem Cell Signaling Scenarios: Evidence and Reasoning (Analyses from the Transcript)
Common task patterns: given a set of observed molecules (signal, receptor, TK1, TK2, TFa, genes) decide which signaling processes are occurring.
Example reasoning patterns illustrated in Pages 14–18:
If signal is present and receptor is present, downstream kinases (TK1, TK2) and transcription factor (TFa) states reveal which branches are active.
Observations where TK2 is not phosphorylated while receptor and TK1 are phosphorylated suggest a phosphatase targeting TK2 may be active (e.g., TK2 dephosphorylated by a phosphatase encoded by TFa target gene).
Partial phosphorylation of TFa can occur when downstream phosphatase activity exists but before full protein turnover clears active copies.
Ubiquitin-dependent proteolysis contributes to turnover that can explain loss of phosphorylated components over time; simultaneously, receptor kinase activity on the receptor remains detectable if degradation is not complete.
If the receptor exhibits kinase activity but TK2 phosphorylation is missing, consider a phosphatase targeting TK2 as a plausible explanation; also consider that signaling could still be reactivated once phosphatase expression declines and newly synthesized components resume phosphorylation.
When TK1 gene expression stops, existing TK1 proteins undergo turnover and decay; over time, this reduces the potential for reactivation unless new TK1 is synthesized.
Core takeaway from these cases: analyzing which components are present, phosphorylated, or degraded helps infer which modules (endocytosis, phosphatase activity, ubiquitin turnover, receptor kinase activity) are functioning or interrupted.
Signals, Feedback, and Core Principles (Foundational Points)
Main points about how signaling works:
Cell behavior changes in response to external signals via signal transduction.
Signals can have short or long durations; duration is shaped by feedback and protein turnover.
Receptors, kinases, phosphatases, and transcription factors are central players.
Kinases add phosphates; phosphatases remove them; activated transcription factors modulate gene expression.
Protein turnover via ubiquitin-dependent proteolysis regulates the lifetime of signaling components.
Receptors can be destroyed or recycled through receptor-mediated endocytosis.
Signaling pathways interact (crosstalk).
Models help predict consequences of mutations or perturbations in pathways.
Positive and negative feedback loops critically influence overall behavior and can generate oscillations or bistable states.
EGFR/MAPK Pathway: Architecture and Core Components
The Epidermal Growth Factor Receptor (EGFR) pathway overview:
EGFR is a receptor tyrosine kinase that dimerizes and autophosphorylates upon EGF binding.
Phosphotyrosines on the receptor serve as docking sites for adaptor proteins (e.g., GRB2) via SH2 domains.
GRB2 recruits SOS, a Ras-GEF, which catalyzes GDP to GTP exchange on Ras, activating Ras.
Activated Ras binds Raf (a MAPKKK), initiating the MAPK cascade: Raf → MEK → ERK.
ERK translocates to the nucleus and activates transcription factors (e.g., ELK-1, c-FOS, c-JUN, c-MYC) to drive cell-cycle progression and proliferation.
Parallel pathway: PI3K/AKT/mTOR axis promotes growth and survival, providing another route by which EGFR signaling supports cancer phenotypes.
Ras anchoring: Ras is tethered to the inner plasma membrane via lipid modifications; proximity to Raf is essential for signaling.
Ras activation cycle (key players):
Ras-GDP is inactive; SOS (Ras-GEF) promotes Ras-GTP activation.
Ras-GTP interacts with Raf to propagate the signal; NF1 (Ras-GAP) stimulates GTP hydrolysis to return Ras to the inactive Ras-GDP state.
Ras-GEF vs Ras-GAP dynamics:
GEF ON, GAP OFF yields active Ras-GTP; conversely, GAP ON terminates Ras signaling.
In many cancers, NF1 is mutated or Ras GTPase activity is impeded, leading to prolonged Ras activation.
GEFs, GAPs, and Ras Regulation (Key Concepts)
GEF: Guanine nucleotide Exchange Factor
Exchanges GDP for GTP on Ras, activating Ras.
Human Ras-GEF example: SOS.
Notation in notes: GEF ON means Ras exchanges GDP for GTP; Ras-GTP is active.
GAP: GTPase Activating Protein
Stimulates GTP hydrolysis on Ras, converting Ras-GTP to Ras-GDP and inactivating Ras.
Human Ras-GAP example: NF1.
Notation: GAP OFF means Ras remains GTP-bound and active.
Activation cycle shorthand (with symbols):
ext{Ras-GDP} igrrow{ ext{GEF (SOS)}} ext{Ras-GTP}
ext{Ras-GTP} igrrow{ ext{GAP (NF1)}} ext{Ras-GDP} + P_i
Additional notes:
GEF/GAP are often localized at the membrane or near membrane-associated components to control Ras activity precisely.
In some cancers, NF1 is mutated, preventing proper deactivation of Ras and leading to sustained signaling.
The Ras-Raf-MEK-ERK Cascade: Signaling Flow and Mechanisms
Sequential activation:
Activated Ras-GTP binds Raf (a serine/threonine kinase) and activates Raf.
Raf phosphorylates MEK (MAPK/ERK kinase).
MEK phosphorylates ERK (MAPK).
ERK phosphorylates a variety of transcription factors (e.g., ELK-1, c-FOS, c-MYC) to drive gene expression changes including Cyclin D1, Cyclin E, and other cell-cycle regulators.
Membrane localization and complex formation:
Ras is membrane-tethered; Raf is recruited to the membrane and activated by RAS-GTP binding.
The interaction often involves scaffold proteins such as Galectin that stabilize signaling complexes at the membrane, promoting efficient signal propagation and kinetic proofreading.
Downstream effects:
ERK translocates to the nucleus and affects transcription factor activity, leading to cell-cycle progression (G1/S).
Immediate-early genes (e.g., c-FOS, c-JUN, c-MYC) are upregulated, which in turn influence cell division and growth programs.
Clinical note: dysregulation of the Ras-Raf-MEK-ERK pathway is a major driver of oncogenesis, with mutations or overactivation contributing to uncontrolled cell proliferation.
Crosstalk and Alternative Pathways: GPCRs and cAMP
In parallel to RTK pathways, G protein-coupled receptors (GPCRs) activate G proteins that exchange GDP for GTP on Gα, leading to downstream effectors such as adenylyl cyclase.
Adenylyl cyclase converts ATP to cyclic AMP (cAMP), which activates Protein Kinase A (PKA).
PKA then phosphorylates transcription factors and other targets to alter gene expression and cellular responses.
Crosstalk: signaling through GPCRs can modulate growth factor signaling (e.g., EGFR/MAPK) by cross-regulating components like Ras, Raf, or transcriptional outputs.
Cancer Context: Ras Mutations and EGFR Pathways
EGFR/MAPK signaling is a frequent oncogenic driver across cancers and is a target for cancer therapy.
Activating mutations in Ras proteins (KRAS, NRAS, HRAS) are among the most common oncogenic alterations in cancers, contributing to persistent signaling even without extracellular cues.
Notable cancers with activating Ras mutations include pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, lung adenocarcinoma, thyroid carcinoma, and others (as enumerated in the provided materials).
Ras mutations tend to cluster at specific codons (e.g., codon 12, 13, 61) with nucleotide substitutions varying by cancer type.
Mechanistic consequence: constitutively active Ras keeps the downstream Raf/MEK/ERK cascade engaged, promoting continuous transcription of pro-proliferative genes such as Cyclin D1 and c-JUN.
NF1 (Ras-GAP) mutations also contribute to elevated Ras activity by reducing GTP hydrolysis and derepressing Ras signaling.
Therapeutic implications:
Directly targeting Ras has been challenging, but strategies include targeting RTKs (EGFR), Ras-GEFs (e.g., SOS), downstream kinases (MEK inhibitors, ERK inhibitors), and synthetic lethality approaches.
Understanding the balance of kinase and phosphatase activities is crucial for predicting pathway behavior and potential resistance mechanisms.
Mutations, Pathway Logic, and Hypothetical Scenarios
Question prompts from the transcript (condensed insights):
If an upstream kinase is inactivated, downstream phospho-proteins lose signaling, but turnover can still affect steady-state levels depending on feedback loops.
When phosphatases are upregulated by pathway activation (e.g., TFa induces a phosphatase targeting TK2), the pathway can show delayed inactivation and potential oscillations before turnover clears kinases.
In oscillating pathways, the sequence of expression/degradation of phosphatases and kinases must be tightly coordinated; otherwise, the system can settle into a persistent ON or OFF state or revert back after turnover.
Critical conclusion: the relative rates of kinase activity, phosphatase action, and protein turnover determine the dynamic behavior (transient vs. sustained signaling, oscillations, or termination).
Problem-Solving Scenarios: Quick References (Selected Items)
If TK2 becomes dephosphorylated by a phosphatase, TK2 activity drops immediately; however, TFa may stay active briefly due to existing phosphorylated copies until turnover degrades them. After turnover, new, unphosphorylated TFa is produced, potentially reactivating the pathway if signal persists.
Receptor-mediated endocytosis: destruction mode would remove the receptor (and potentially downstream signaling components) from the membrane; recycling mode returns the receptor, enabling re-sensitization to signal upon re-exposure.
In the Ras pathway, even if Ras GTPase activity is defective (Ras cannot hydrolyze GTP effectively), upstream events can still be blocked by preventing signal binding to EGFR or inhibiting SOS, or by restoring NF1 activity; blocking Raf kinase activity or disrupting Raf-Ras binding would also suppress signaling downstream.
In cancer, activating mutations downstream of EGFR (Ras, Raf, MEK, ERK) can sustain proliferative signaling even without ligand; therapies often target downstream kinases (MEK inhibitors, ERK inhibitors) or upstream receptors (EGFR inhibitors) to curb signaling.
Summary of Key Pathway Elements (Condensed List)
Signaling concepts:
Signal transduction transmits external cues to the nucleus to change gene expression.
Duration and intensity depend on kinase/phosphatase balance and protein turnover.
Oscillations require feedback, rapid degradation, and shut-off of phosphatase expression.
Core pathway architecture:
EGFR activation by EGF → Grb2/SOS → Ras-GTP → Raf → MEK → ERK → nucleus.
Parallel PI3K/AKT/mTOR axis modulates growth and survival.
Regulation by GEFs and GAPs:
SOS (GEF) activates Ras by promoting GDP → GTP exchange.
NF1 (GAP) inactivates Ras by stimulating GTP hydrolysis.
Ras and Raf dynamics:
Ras-GTP directly activates Raf; Raf activation leads to MEK activation and downstream ERK signaling.
Localization at the membrane and scaffold interactions promote signaling fidelity.
Receptor fate and endocytosis:
Receptors can be recycled or degraded, shaping the duration of signaling.
Cancer implications:
Ras mutations and NF1 loss contribute to sustained EGFR signaling and tumorigenesis.
Therapeutic strategies target RTKs, Ras regulators, or downstream kinases.
Mathematical and Conceptual Notes (Equations and Variables)
Ras activation cycle (conceptual):
Activation step:
Inactivation step:
Signaling cascade (qualitative):
Phosphatase competition (qualitative):
If phosphatase activity outruns kinase activity, net phosphorylation of substrates becomes low; if kinase activity dominates, substrates stay phosphorylated longer. The relative rates determine phosphorylation state distributions.
Practical Implications and Real-World Relevance
Understanding EGFR/MAPK signaling helps explain how external growth cues control cell division and how mutations lead to cancerous growth.
Targeted therapies often aim to interrupt key nodes in these pathways (e.g., EGFR inhibitors, Ras pathway inhibitors) to reduce aberrant cell proliferation.
Crosstalk with GPCRs and other pathways means that cellular responses can be context-dependent and variable across tissues.
Knowledge of receptor endocytosis informs strategies to modulate receptor sensitivity and receptor downregulation in disease contexts.
Quick References (Important Takeaways)
The phosphatase-mediated negative feedback loop can generate oscillations when combined with protein turnover and transcriptional control of phosphatase genes.
Receptor-mediated endocytosis can either terminate signaling (destruction mode) or reset signaling capacity (recycling mode).
In the EGF/MAPK pathway, Ras acts as a binary switch controlled by GEFs (SOS) and GAPs (NF1); mutations in Ras or loss of NF1 promote sustained signaling and cancer progression.
The balance of kinase vs phosphatase activity, along with protein turnover, shapes the duration and dynamics of signaling responses.